Once-weekly antidiabetic agonist is launched, what is its marketability in Korea?
Since Trulicity, a Lilly’s once-weekly antidiabetic agent, a GLP-1 receptor agonist, acquired product approval, the industry has turned attention from daily treatments to weekly treatments.
Particularly, as Hanmi Pharm has recently transferred the monthly – at the longest – GLP-1 receptor agonis...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
